{
    "organizations": [],
    "uuid": "8464e13b6199291a6ef9e15f8e0ed335e17801d3",
    "author": "",
    "url": "https://www.reuters.com/article/brief-gilead-and-verily-announce-scienti/brief-gilead-and-verily-announce-scientific-collaboration-idUSFWN1S71C7",
    "ord_in_thread": 0,
    "title": "BRIEF-Gilead And Verily Announce Scientific Collaboration",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 30 (Reuters) - Gilead Sciences Inc:\n* GILEAD AND VERILY ANNOUNCE SCIENTIFIC COLLABORATION TO IDENTIFY AND UNDERSTAND IMMUNOLOGICAL AND MOLECULAR DRIVERS OF INFLAMMATORY DISEASES\n* GILEAD SCIENCES INC - VERILY TO DEPLOY ITS IMMUNOSCAPE PLATFORM TO GENERATE INSIGHTS FROM GILEAD CLINICAL TRIALS\n* GILEAD SCIENCES INC - THREE-YEAR COLLABORATION WITH VERILY LIFE SCIENCES Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ",
    "published": "2018-04-30T23:43:00.000+03:00",
    "crawled": "2018-05-01T00:02:22.006+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "gilead",
        "science",
        "inc",
        "gilead",
        "verily",
        "announce",
        "scientific",
        "collaboration",
        "identify",
        "understand",
        "immunological",
        "molecular",
        "driver",
        "inflammatory",
        "disease",
        "gilead",
        "science",
        "inc",
        "verily",
        "deploy",
        "immunoscape",
        "platform",
        "generate",
        "insight",
        "gilead",
        "clinical",
        "trial",
        "gilead",
        "science",
        "inc",
        "collaboration",
        "verily",
        "life",
        "science",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}